Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2013-02-20
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild BLOOD CHOLESTEROL INCREASED — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-06 (study day 15.0); relationship: NONE
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-02-20 (study day 1.0); relationship: PROBABLE
Data queries
No data queries.